News and Events
Celebrating CCR Careers: Alan Rein, Ph.D.
Alan Rein, Ph.D., is a known expert in the field of viral assembly, particularly in retroviruses like the human immunodeficiency virus (HIV). After an extensive career studying molecular mechanisms of retroviral replication and pathogenesis, he has announced his retirement.
Read More
Clinical trial researching therapy for esophageal cancers
A clinical trial led by David S. Schrump, M.D., MBA., FACS, Chief and Senior Investigator in the Thoracic Surgery Branch, is researching a combination vaccine and drug therapy for esophageal cancers.
Read More
New biomaterial enhances cancer vaccine effectiveness to help eliminate cancer in mice
Scientists have created a new type of cancer vaccine approach that uses a biomaterial that attracts immune cells and localizes the delivery of the vaccines. In mice, the biomaterial combined with a cancer vaccine was able to cure 50 to 75% of their tumors.
Read More
Steven Rosenberg receives AACR Award for Lifetime Achievement in Cancer Research
The American Association for Cancer Research (AACR) has awarded Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, the AACR Award for Lifetime Achievement in Cancer Research. He is being recognized for his paramount contributions to cancer research and patient care, most notably his pioneering research in establishing cancer immunotherapy as a major treatment strategy for many cancer types. He will receive the award at the 2024 AACR Annual Meeting.
Read More
Clinical trial researching BRCA1-Associated Protein-1 mutations
A clinical trial led by David S. Schrump, M.D., M.B.A., FACS, Chief and Senior Investigator in the Thoracic Surgery Branch, is researching a combination drug therapy for BRCA1-Associated Protein-1 mutations.
Read More
Clinical trial researching therapy for B-cell lymphoma
A clinical trial led by Kathryn A. Lurain, M.D., M.P.H., Assistant Research Physician in the HIV and AIDS Malignancy Branch, is researching a drug for B-cell lymphoma.
Read More
Celebrating CCR Careers: Jonathan R. Keller, Ph.D.
Jonathan R. Keller, Ph.D., an experimental hematologist who discovered interleukin-3 (IL-3) and explored the factors that give rise to leukemia, announces his retirement.
Read More
India’s First Homegrown CAR T-Cell Therapy Has Roots in NCI Collaboration
In October 2023, India’s counterpart to the US Food and Drug Administration, the Central Drugs Standard Control Organization, approved NexCAR19, an effective, low-cost CAR-T cell therapy. The development of the therapy was made possible by a years-long collaborative journey between the Indian Institute of Technology Bombay and Tata Memorial Centre in Mumbai with NCI researchers at the NIH Clinical Center. As India’s first approved CAR-T cell therapy, the treatment will be manufactured in Mumbai and is affordable for many.
Read More
Aligned Blog: The Intersection of Art and Science: Honoring Black History Month
This year, Black History Month celebrates "Art as a Platform for Social Justice." In this edition of Aligned, Chabelis Byamana, Program Specialist in CCR’s Office of Equity and Inclusion, explores the intersection of art and science, asking what our science tells us about how we see the world, who we center and who we leave out.
Read More
Clinical trial researching therapy for RUNX1 mutations
A clinical trial led by Lea C. Cunningham, M.D., Associate Research Physician in the Immune Deficiency Cellular Therapy Program, is researching a drug for RUNX1 mutations.
Read More
The liver controls intestinal health through the PEDF protein
A new study reveals how the liver and gut communicate to regulate stem cell expansion in the repair of damaged intestinal tissue. The finding, from the lab of Chuan Wu, M.D., Ph.D., has important implications for a lipid-lowering drug that affects that communication.
Read More